No profile data available.
Medigene AG (MDGEF) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Munich, Germany, with about 87 full-time employees.
It reported revenue of 6.03 million EUR for fiscal year 2023, down 80.7% from fiscal year 2022, and net income of -16.18 million EUR. In Q2 2024 (the quarter ended June 30, 2024) revenue was 1.46 million EUR. Its market capitalization was $38.17 million as of May 14, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2023; market data as of May 14, 2026.
Medigene AG is in the process of liquidation of its remaining assets. Previously, the company was engaged in the development of T-cell therapies for the treatment of cancer. Medigene AG was founded in 1994 and is headquartered in Munich, Germany.
Medigene reported 6.03 million EUR in revenue for fiscal year 2023, down 80.7% from 31.25 million EUR in fiscal year 2022. In Q2 2024 revenue was 1.46 million EUR.
$38.17 million as of May 14, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Impact BioMedical Inc. (IBO), Telomir Pharmaceuticals, Inc. (TELO), Metagenomi, Inc. (MGX), Growth Stalk Holdings Corp (GSTK).